



Ryo Nishikawa

Japan

Ryo Nishikawa, MD is Professor Emeritus of Neurosurgery, Saitama Medical University, and Director, Nerima-station Rehabilitation Hospital since 2023. His work has been focused on development of novel therapeutics for malignant brain tumors, both in adults and children. He was the former president of the Japanese Society for Neuro-oncology, the former chief of the Brain Tumor Group of Japan Clinical Oncology Group, and was the president of the Asian Society for Neuro-Oncology until 2023. His major works are:

1. Nishikawa, R, Cavenee, WK, Su Huang, H-J, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. USA. 91:7727-7731, 1994
2. Chinot OL, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709-722, 2014.
3. Murray MJ, Nishikawa R, et al. Consensus on the management of intracranial germ-cell tumours. Lancet Oncol 2015;16:e470-477
4. Ichimura K, Nishikawa R, et al. Intracranial Germ Cell Tumor Genome Analysis Consortium. Recurrent neomorphic mutations of MTOR in central nervous system and testicular germ cell tumors may be targeted for therapy. Acta Neuropathol 131:889-901, 2016
5. Perry JR, Nishikawa R, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 376:1027-1037, 2017.
6. Nakamura H, Nishikawa R, et al. The Japan Society for Neuro-Oncology. Guideline on the Diagnosis and Treatment of Central Nervous System Germ Cell Tumors. Neuro Oncol. 2022 Apr 1;24(4):503-515.doi: 10.1093/neuonc/noab242.
7. Sonehara K, Nishikawa R, et al. A common deletion at BAK1 reduces enhancer activity and confers risk of intracranial germ cell tumors. Nature Communications 2022 Aug 2;13(1):4478. doi: 10.1038/s41467-022-32005-9.PMID: 35918310
8. Mishima K, Nishikawa R, et al. Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C. Neuro Oncol 2023 Apr 6;25(4):687-698. doi: 10.1093/neuonc/noac246.